Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet. Click here to read an analysis of APLS ...

Activation of the ‘complement system’ helps trigger dangerous sickle-cell-disease outcome Research in mice suggests this system plays a key role in acute chest syndrome and offers a potential ...

The complement system and neutrophils constitute the two main pillars of the host innate immune defense against infection by bacterial pathogens. Here, we identify T-Mac, a novel virulence factor of ...

“The GALE study is the largest long-term extension in GA and the results highlight the benefit of C3/C3b complement inhibition with pegcetacoplan in patients who did not receive active treatment in ...

Send comments and news tips to news@medscape.net. Cite this: Novel Drug Targeting C3/C3b Shows Benefits in Rare C3 Glomerulopathy and Primary IC-MPGN - Medscape - October 29, 2024.

Advances in immunosuppression have decreased the incidence of acute rejection, but the development of vasculopathy in the coronary arteries of transplants continues to limit the survival of cardiac ...

C3b is a recognizable ligand for circulating macrophages, which bind to the subunit through the CR1 receptor and engulf the entity. The other subunit resulting from C3 cleavage is C3a, an ...

This fundamental study significantly advances our understanding of how parasites evade the host complement immune system. The new cryo-EM structure of the trypanosome receptor ISG65 bound to ...

NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin antibody, known as NM3086.